Routine blood examinations combined with morphological analysis for the diagnosis of myelodysplastic/myeloproliferative neoplasms

Wu,Huanling; Sun,Hui; Zhang,Zhifen; Li,Xiangli; Li,Yuantang; Li,Li; Xu,Rui; Wang,Zie; Tian,Wenjun

doi:10.3892/ol.2016.5165

Routine blood examinations combined with morphological analysis for the diagnosis of myelodysplastic/myeloproliferative neoplasms

Authors:
- Huanling Wu
- Hui Sun
- Zhifen Zhang
- Xiangli Li
- Yuantang Li
- Li Li
- Rui Xu
- Zie Wang
- Wenjun Tian
View Affiliations

Affiliations: Department of Clinical Laboratory Medicine, Shandong Provincial Hospital Affiliated to Shandong University, Jinan, Shandong 250021, P.R. China, Department of Clinical Laboratory, Hospital of Traditional Chinese Medicine, Shouguang, Shandong 262700, P.R. China
Published online on: September 21, 2016 https://doi.org/10.3892/ol.2016.5165
Pages: 4245-4251

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

In 2008, the World Health Organization (WHO) introduced a new hematological neoplasm category; myelodysplastic/myeloproliferative neoplasms (MDS/MPN), which included four main subcategories. This disease is often misdiagnosed, which delays effective therapy. The present study evaluated the role of routine blood examinations and morphological analysis of peripheral blood cells in the reliable diagnosis of MDS/MPN. In total, 236 adult MDS/MPN patients were analyzed. The analysis included 10 routine blood parameters measured using a Sysmex XE‑2100™, 3 differential percentage parameters and 7 morphological features of peripheral blood cells which were analyzed by optical microscopy, and 3 differential absolute count numbers obtained based on the corresponding differential percentages and absolute count of blood cells. The parameters were compared among the subcategories and a value of P<0.05 was considered to indicate a statistically significant difference. The median white blood cell and hemoglobin counts of the patients were 18.0x109/l and 88 g/l, respectively. The proportion of monocytes increased to 8% (1.82x109/l), the proportion of blast cells increased to 1% (0.5x109/l) and that of neutrophil precursors increased to 10% (1.98x109/l). A total of 87% of all patients presented with hypogranulation and 71% presented with abnormal condensed nuclear chromatin in granulocytes. Atypical monocytes were observed in 73% of all patients and Pseudo‑Pelger cells were observed in 60%. Significant differences were detected among the subcategories. The present study demonstrated that combining blood routine parameters and the morphological analysis of peripheral blood cells have an essential role in the reliable diagnosis of MDS/MPN based on WHO categories.

View Figures

View References

1	Vardiman JW, Harris NL and Brunning RD: The World Health Organization (WHO) classification of the myeloid neoplasms. Blood. 100:2292–2302. 2002. View Article : Google Scholar : PubMed/NCBI
2	Geyer JT and Orazi A: Myeloproliferative neoplasms (BCR-ABL1 negative) and myelodysplastic/myeloproliferative neoplasms: Current diagnostic principles and upcoming updates. Int J Lab Hematol. 38(Suppl 1): S12–S19. 2016. View Article : Google Scholar
3	Orazi A and Germing U: The myelodysplastic/myeloproliferative neoplasms: Myeloproliferative diseases with dysplastic features. Leukemia. 22:1308–1319. 2008. View Article : Google Scholar : PubMed/NCBI
4	Mughal TI, Cross NC, Padron E, Tiu RV, Savona M, Malcovati L, Tibes R, Komrokji RS, Kiladjian JJ, Garcia-Manero G, et al: An International MDS/MPN Working Group's perspective and recommendations on molecular pathogenesis, diagnosis and clinical characterization of myelodysplastic/myeloproliferative neoplasms. Haematologica. 100:1117–1130. 2015. View Article : Google Scholar : PubMed/NCBI
5	Shibata A, Bennett JM, Castoldi GL, Catovsky D, Flandrin G, Jaffe ES, Katayama I, Nanba K, Schmalzl F, Yam LT, et al: Recommended methods for cytological procedures in haematology. International Committee for Standardization in Haematology (ICSH). Clin Lab Haematol. 7:55–74. 1985.
6	Wu H, Bian S, Chu J, Zhong X, Sun H, Zhang B and Lu Z: Characteristics of the four subtypes of myelodysplastic/myeloproliferative neoplasms. Exp Ther Med. 5:1332–1338. 2013.PubMed/NCBI
7	Beran M, Wen S, Shen Y, Onida F, Jelinek J, Cortes J, Giles F and Kantarjian H: Prognostic factors and risk assessment in chronic myelomonocytic leukemia: Validation study of the M.D. Anderson Prognostic Scoring System. Leuk Lymphoma. 48:1150–1160. 2007. View Article : Google Scholar
8	Germing U, Strupp C, Knipp S, Kuendgen A, Giagounidis A, Hildebrandt B, Aul C, Haas R, Gattermann N and Bennett JM: Chronic myelomonocytic leukemia in the light of the WHO proposals. Haematologica. 92:974–977. 2007. View Article : Google Scholar : PubMed/NCBI
9	Parikh SA and Tefferi A: Chronic myelomonocytic leukemia: 2013 update on diagnosis, risk stratification, and management. Am J Hematol. 87:610–619. 2012. View Article : Google Scholar : PubMed/NCBI
10	Benton CB, Nazha A, Pemmaraju N and Garcia-Manero G: Chronic myelomonocytic leukemia: Forefront of the field in 2015. Crit Rev Oncol Hematol. 95:222–242. 2015. View Article : Google Scholar : PubMed/NCBI
11	Koldehoff M, Steckel NK, Hegerfeldt Y, Ditschkowski M, Beelen DW and Elmaagacli AH: Clinical course and molecular features in 21 patients with atypical chronic myeloid leukemia. Int J Lab Hematol. 34:e3–e5. 2012. View Article : Google Scholar : PubMed/NCBI
12	Vardiman JW, Thiele J, Arber DA, Brunning RD, Borowitz MJ, Porwit A, Harris NL, Le Beau MM, Hellstrom-Lindberg E, Tefferi A and Bloomfield CD: The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood. 114:937–951. 2009. View Article : Google Scholar : PubMed/NCBI
13	Breccia M, Biondo F, Latagliata R, Carmosino I, Mandelli F and Alimena G: Identification of risk factors in atypical chronic myeloid leukemia. Haematologica. 91:1566–1568. 2006.PubMed/NCBI
14	Xubo G, Xingguo L, Xianguo W, Rongzhen X, Xibin X, Lin W, Lei Z, Xiaohong Z, Genbo X and Xiaoying Z: The role of peripheral blood, bone marrow aspirate and especially bone marrow trephine biopsy in distinguishing atypical chronic myeloid leukemia from chronic granulocytic leukemia and chronic myelomonocytic leukemia. Eur J Haematol. 83:292–301. 2009. View Article : Google Scholar : PubMed/NCBI
15	Wang SA, Hasserjian RP, Fox PS, Rogers HJ, Geyer JT, Chabot-Richards D, Weinzierl E, Hatem J, Jaso J, Kanagal-Shamanna R, et al: Atypical chronic myeloid leukemia is clinically distinct from unclassifiable myelodysplastic/myeloproliferative neoplasms. Blood. 123:2645–2651. 2014. View Article : Google Scholar : PubMed/NCBI
16	Onida F, Ball G, Kantarjian HM, Smith TL, Glassman A, Albitar M, Scappini B, Rios MB, Keating MJ and Beran M: Characteristics and outcome of patients with Philadelphia chromosome negative, bcr/abl negative chronic myelogenous leukemia. Cancer. 95:1673–1684. 2002. View Article : Google Scholar : PubMed/NCBI
17	Triantafyllidis I, Ciobanu A, Stanca O, Draghici C, Angelescu S and Tapelea E: Peculiarities in the Diagnosis Approach of MDS/MPN-U Patients. Maedica (Buchar). 7:173–176. 2012.PubMed/NCBI
18	Seo JY, Lee KO, Kim SH, Kim K, Jung CW, Jang JH and Kim HJ: Clinical significance of SF3B1 mutations in Korean patients with myelodysplastic syndromes and myelodysplasia/myeloproliferative neoplasms with ring sideroblasts. Ann Hematol. 93:603–608. 2014. View Article : Google Scholar : PubMed/NCBI
19	DiNardo CD, Daver N, Jain N, Pemmaraju N, Bueso-Ramos C, Yin CC, Pierce S, Jabbour E, Cortes JE, Kantarjian HM, et al: Myelodysplastic/myeloproliferative neoplasms, unclassifiable (MDS/MPN, U): Natural history and clinical outcome by treatment strategy. Leukemia. 28:958–961. 2014. View Article : Google Scholar : PubMed/NCBI
20	Hyjek E and Vardiman JW: Myelodysplastic/myeloproliferative neoplasms. Semin Diagn Pathol. 28:283–297. 2011. View Article : Google Scholar : PubMed/NCBI
21	Goasguen JE, Bennett JM, Bain BJ, Vallespi T, Brunning R and Mufti GJ: International Working Group on Morphology of Myelodysplastic Syndrome: Morphological evaluation of monocytes and their precursors. Haematologica. 94:994–997. 2009. View Article : Google Scholar : PubMed/NCBI
22	Hall J and Foucar K: Diagnosing myelodysplastic/myeloproliferative neoplasms: Laboratory testing strategies to exclude other disorders. Int J Lab Hematol. 32:559–571. 2010. View Article : Google Scholar : PubMed/NCBI
23	Vermi W, Facchetti F, Rosati S, Vergoni F, Rossi E, Festa S, Remotti D, Grigolato P, Massarelli G and Frizzera G: Nodal and extranodal tumor-forming accumulation of plasmacytoid monocytes/interferon-producing cells associated with myeloid disorders. Am J Surg Pathol. 28:585–595. 2004. View Article : Google Scholar : PubMed/NCBI
24	Tiu RV and Sekeres MA: Making sense of the myelodysplastic/myeloproliferative neoplasms overlap syndromes. Curr Opin Hematol. 21:131–140. 2014. View Article : Google Scholar : PubMed/NCBI
25	Cazzola M, Malcovati L and Invernizzi R: Myelodysplastic/myeloproliferative neoplasms. Hematology Am Soc Hematol Educ Program. 2011:264–272. 2011.PubMed/NCBI
26	Kern W, Bacher U, Schnittger S, Alpermann T, Haferlach C and Haferlach T: Multiparameter flow cytometry reveals myelodysplasia-related aberrant antigen expression in myelodysplastic/myeloproliferative neoplasms. Cytometry B Clin Cytom. 84:194–197. 2013. View Article : Google Scholar : PubMed/NCBI